Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer (Q35944817)

11 August 2017

Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer (English)

1 reference

11 August 2017

0 references

1 reference

1 reference

Manish Patel

1

1 reference

11 August 2017

Sarah Hoffe

2

1 reference

11 August 2017

Mokenge Malafa

3

1 reference

11 August 2017

Pamela Hodul

4

1 reference

11 August 2017

Jason Klapman

5

1 reference

11 August 2017

Barbara Centeno

6

1 reference

11 August 2017

Jongphil Kim

7

1 reference

11 August 2017

James Helm

8

1 reference

11 August 2017

Tiffany Valone

9

1 reference

11 August 2017

Gregory Springett

10

1 reference

11 August 2017

25 April 2011

1 reference

Journal of Surgical Oncology

11 August 2017

1 reference

11 August 2017

104

1 reference

11 August 2017

2

1 reference

11 August 2017

155-161

1 reference

Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3347705

Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3347705

PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3347705

The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3347705

Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3347705

Effect of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3347705

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3347705

Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3347705

Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3347705

Toxicity and response criteria of the Eastern Cooperative Oncology Group

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3347705

Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3347705

Gemcitabine, paclitaxel, and radiation for locally advanced pancreatic cancer: a Phase I trial

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3347705

Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3347705

Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3347705

Nonparametric Estimation from Incomplete Observations

24 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FJSO.21954

Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial

21 January 2018

1 reference

12 December 2020

Preoperative staging and assessment of resectability of pancreatic cancer

1 reference

12 December 2020

Neoadjuvant therapy for unresectable pancreatic adenocarcinoma

1 reference

12 December 2020

A pilot study of preoperative chemoradiation for patients with localized adenocarcinoma of the pancreas

1 reference

12 December 2020

Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study

1 reference

12 December 2020

Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas

1 reference

12 December 2020

Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy

1 reference

12 December 2020

Identifiers

DOI

10.1002/JSO.21954

1 reference

11 August 2017

1 reference

11 August 2017

PubMed publication ID

21520097

1 reference